> Also taking SSRIs near MDMA administration is one of the worst pieces of what is doubtless intended as harm reduction advice I’ve ever seen. You don’t hand people a recipe for serotonin syndrome because of a small scale rat test or two.
you have a deep understanding of releaser pharmacology if you state this. don't take it from me though--matthew baggott, one of the leading researchers studying enactogen pharmacology recommends doing this exact thing
Okay, I looked at Baggott's work a little more. Here are my primary concerns:
1. He's talking his book to a certain extent. This is his life's work and he runs a company in this space (though a B corp) so he will have a bias here. That's fine overall, as it may help balance people unfairly biased against psychedelics, but it's worth remembering. I'm not saying this to impugn his character so much as to point out everyone has biases, and someone in his position likely has strong ones, even if partially-founded.
2. He believes an SSRI alleviates negative symptoms, but we don't know it does more than alleviate the comedown. It appears his endpoint was cognitive performance post-use, not long-term damage that may appear once off the SSRI.
3. This doesn't touch the dopaminergic risks of amphetamines, which are substantial.
A few exploratory bits of research into one potential way to alleviate the acute effects post-administration don't translate to an established method to use this in a remotely-safe fashion.
you have a deep understanding of releaser pharmacology if you state this. don't take it from me though--matthew baggott, one of the leading researchers studying enactogen pharmacology recommends doing this exact thing